Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval

Maher Kurdi,1 Nadeem Shafique Butt,2 Saleh Baeesa,3 Abudukadeer Kuerban,4 Yazid Maghrabi,5 Anas Bardeesi,5 Rothaina Saeedi,3 Badrah S Alghamdi,6 Ahmed I Lary,7 Fawaz Mohamed,1 Sahar Hakamy8 1Department of Pathology, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi A...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kurdi M, Butt NS, Baeesa S, Kuerban A, Maghrabi Y, Bardeesi A, Saeedi R, Alghamdi BS, Lary AI, Mohamed F, Hakamy S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	glioblastoma idh1 mutation wt1 expression chemotherapies pcr sensitivity Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f5fce0df4fcc440a85ba02b865afaceb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f5fce0df4fcc440a85ba02b865afaceb
record_format	dspace
spelling	oai:doaj.org-article:f5fce0df4fcc440a85ba02b865afaceb2021-12-02T16:17:56ZSensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval1177-5491https://doaj.org/article/f5fce0df4fcc440a85ba02b865afaceb2021-07-01T00:00:00Zhttps://www.dovepress.com/sensitivity-assessment-of-wilms-tumor-gene-wt1-expression-in-glioblast-peer-reviewed-fulltext-article-BTThttps://doaj.org/toc/1177-5491Maher Kurdi,1 Nadeem Shafique Butt,2 Saleh Baeesa,3 Abudukadeer Kuerban,4 Yazid Maghrabi,5 Anas Bardeesi,5 Rothaina Saeedi,3 Badrah S Alghamdi,6 Ahmed I Lary,7 Fawaz Mohamed,1 Sahar Hakamy8 1Department of Pathology, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 2Department of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 3Division of Neurosurgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 4Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 5Department of Neuroscience, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia; 6Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 7Section of Neurosurgery, Department of Surgery, King Abdulaziz Medical City, Jeddah, Kingdom of Saudi Arabia; 8Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Kingdom of Saudi ArabiaCorrespondence: Maher KurdiDepartment of Pathology, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi ArabiaTel +966 556655467Email Ahkurdi@kau.edu.saPurpose: Wilms tumor 1 (WT1) gene has recently shown a role in gliomagenesis, making it a potential immunotherapy target in glioblastomas. We aimed to investigate the most sensitive method to detect WT1 expression in glioblastoma and explore the relationship between WT1 expression, IDH1 mutation and recurrence interval.Patients and Methods: Clinical data were collected from 44 patients with glioblastomas, treated with adjuvant therapies. WT1 expression was assessed in all cases using immunohistochemistry (IHC), while its gene expression was assessed in 13 clustered samples using polymerase chain reaction (qPCR). IDH1 mutation was assessed using IHC. The sensitivity between IHC and RT-qPCR was examined. Kaplan–Meier curves were used to compare the recurrence-free interval (RFI) between IDH1 and WT1 expression groups.Results: IDH1wildtype was found in 26 cases (59.1%) and the remaining 18 cases (40.9%) were IDH1mutant. Through IHC, WT1 was overexpressed in 32 cases (72.7%), partially expressed in 9 cases (20.5%) and not expressed in only 3 cases. For the 13 cases tested by qPCR, 6 cases showed WT1 upregulation and 7 cases showed WT1 downregulation. There was no significant difference in WT1 expression among cases with different RNA concentrations regardless the testing method (p-value > 0.05). However, the difference between IHC and qPCR was significant. IDH1mutant cases with WT1 overexpression showed significant difference in RFI (p-value =0.048).Conclusion: Parallel testing for WT1 expression using IHC and qPCR is not reliable. However, IHC provides more accurate results. Moreover, IDH1mutant glioblastomas with WT1 overexpression are associated with late RFI particularly if temozolomide with additional chemotherapies are used.Keywords: glioblastoma, IDH1 mutation, WT1 expression, chemotherapies, PCR sensitivityKurdi MButt NSBaeesa SKuerban AMaghrabi YBardeesi ASaeedi RAlghamdi BSLary AIMohamed FHakamy SDove Medical Pressarticleglioblastomaidh1 mutationwt1 expressionchemotherapiespcr sensitivityMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 289-297 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	glioblastoma idh1 mutation wt1 expression chemotherapies pcr sensitivity Medicine (General) R5-920
spellingShingle	glioblastoma idh1 mutation wt1 expression chemotherapies pcr sensitivity Medicine (General) R5-920 Kurdi M Butt NS Baeesa S Kuerban A Maghrabi Y Bardeesi A Saeedi R Alghamdi BS Lary AI Mohamed F Hakamy S Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval
description	Maher Kurdi,1 Nadeem Shafique Butt,2 Saleh Baeesa,3 Abudukadeer Kuerban,4 Yazid Maghrabi,5 Anas Bardeesi,5 Rothaina Saeedi,3 Badrah S Alghamdi,6 Ahmed I Lary,7 Fawaz Mohamed,1 Sahar Hakamy8 1Department of Pathology, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 2Department of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 3Division of Neurosurgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 4Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 5Department of Neuroscience, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia; 6Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 7Section of Neurosurgery, Department of Surgery, King Abdulaziz Medical City, Jeddah, Kingdom of Saudi Arabia; 8Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Kingdom of Saudi ArabiaCorrespondence: Maher KurdiDepartment of Pathology, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi ArabiaTel +966 556655467Email Ahkurdi@kau.edu.saPurpose: Wilms tumor 1 (WT1) gene has recently shown a role in gliomagenesis, making it a potential immunotherapy target in glioblastomas. We aimed to investigate the most sensitive method to detect WT1 expression in glioblastoma and explore the relationship between WT1 expression, IDH1 mutation and recurrence interval.Patients and Methods: Clinical data were collected from 44 patients with glioblastomas, treated with adjuvant therapies. WT1 expression was assessed in all cases using immunohistochemistry (IHC), while its gene expression was assessed in 13 clustered samples using polymerase chain reaction (qPCR). IDH1 mutation was assessed using IHC. The sensitivity between IHC and RT-qPCR was examined. Kaplan–Meier curves were used to compare the recurrence-free interval (RFI) between IDH1 and WT1 expression groups.Results: IDH1wildtype was found in 26 cases (59.1%) and the remaining 18 cases (40.9%) were IDH1mutant. Through IHC, WT1 was overexpressed in 32 cases (72.7%), partially expressed in 9 cases (20.5%) and not expressed in only 3 cases. For the 13 cases tested by qPCR, 6 cases showed WT1 upregulation and 7 cases showed WT1 downregulation. There was no significant difference in WT1 expression among cases with different RNA concentrations regardless the testing method (p-value > 0.05). However, the difference between IHC and qPCR was significant. IDH1mutant cases with WT1 overexpression showed significant difference in RFI (p-value =0.048).Conclusion: Parallel testing for WT1 expression using IHC and qPCR is not reliable. However, IHC provides more accurate results. Moreover, IDH1mutant glioblastomas with WT1 overexpression are associated with late RFI particularly if temozolomide with additional chemotherapies are used.Keywords: glioblastoma, IDH1 mutation, WT1 expression, chemotherapies, PCR sensitivity
format	article
author	Kurdi M Butt NS Baeesa S Kuerban A Maghrabi Y Bardeesi A Saeedi R Alghamdi BS Lary AI Mohamed F Hakamy S
author_facet	Kurdi M Butt NS Baeesa S Kuerban A Maghrabi Y Bardeesi A Saeedi R Alghamdi BS Lary AI Mohamed F Hakamy S
author_sort	Kurdi M
title	Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval
title_short	Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval
title_full	Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval
title_fullStr	Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval
title_full_unstemmed	Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval
title_sort	sensitivity assessment of wilms tumor gene (wt1) expression in glioblastoma using qpcr and immunohistochemistry and its association with idh1 mutation and recurrence interval
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/f5fce0df4fcc440a85ba02b865afaceb
work_keys_str_mv	AT kurdim sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT buttns sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT baeesas sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT kuerbana sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT maghrabiy sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT bardeesia sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT saeedir sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT alghamdibs sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT laryai sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT mohamedf sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT hakamys sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval
_version_	1718384268666732544

Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval

Ejemplares similares